Statins and bones

CMAJ. Canadian Medical Association Journal

Volumn 164, Issue 6, 2001, Pages 803-805

  Moghadasian, M H ^a   Frohlich, J J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; BONE ATROPHY; BONE MINERAL; BONE STRENGTH; CELL DIFFERENTIATION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG MECHANISM; ENZYME INHIBITION; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; NOTE; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PATIENT COMPLIANCE; PROTEIN EXPRESSION;

EID: 0034988339     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (24)

1. Current perspectives on statins
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischemic disease (LIPID) study group
3. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators
5. Clinical pharmacology of 3-hydroxy-3-methyglutaryl Co-enzyme A reductase inhibitors
6. Low-density lipoprotein-independent effects of statins
7. Stimulation of bone formation in vitro and in rodents by statins
8. HMG-CoA reductase inhibitors and the risk of fractures
9. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
10. Inhibitors of hydroxymethyglutaryl-coenzyme A reductase and risk of fracture among older women
11. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
12. Statin use, bone mass and fracture: An analysis of two prospective studies
13. How many women have osteoporosis?
14. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
15. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
16. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone - (1-34): A randomized controlled trial
17. Calcitonin
18. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal women
19. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-remodeling kinase
20. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
21. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
22. Histomorphometric assessment of long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
23. Progression of aortic calcification is associated with metacarpal bone loss during menopause. A population-based longitudinal study
24. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering